{"transactions":[{"id":706996,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"officer":true,"officer_title":"CFO and Treasurer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-18T01:00:20.000Z","date":"2026-07-16","kind":"grant","planned":false,"acquired":true,"shares":136363,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted to the Reporting Person on July 16, 2026, and will vest over four years, with 25% of the shares subject to the option vesting on the one-year anniversary of the date of grant, and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, becoming fully vested on July 16, 2030 in accordance with the Plan, subject to the Reporting Person's continued service as of the applicable vesting date."}],"balance_after":136363,"derivative":{"exercise_price":8.81,"expiration_date":"2036-07-16","underlying":"Common Stock","underlying_shares":136363},"source":{"system":"sec-edgar","filing":"0001140361-26-028844","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000114036126028844/form4.xml","form_type":"4"}},{"id":706995,"issuer":{"id":4477,"kind":"organization","name":"ADMA BIOLOGICS, INC."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"officer":true,"officer_title":"CFO and Treasurer"}}],"security":"Common Stock","published_at":"2026-07-18T01:00:20.000Z","date":"2026-07-16","kind":"grant","planned":false,"acquired":true,"shares":85130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the \"Plan\"), subject to the Reporting Person's continued service as of the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes, as of the transaction date, (i) 85,130 unvested RSUs granted on July 16, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; and (ii) 58,019 unvested RSUs granted on December 8, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":143149,"source":{"system":"sec-edgar","filing":"0001140361-26-028844","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000114036126028844/form4.xml","form_type":"4"}},{"id":1139152,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T13:26:25.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6950,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."}],"balance_after":0,"derivative":{"exercise_price":5.77,"expiration_date":"2035-02-21","underlying":"Common Stock","underlying_shares":6950},"source":{"system":"sec-edgar","filing":"0001104659-25-051349","document":"tm2515648-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000110465925051349/tm2515648-10_4seq1.xml","form_type":"4"}},{"id":1139151,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-21T13:26:25.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration)."}],"balance_after":0,"derivative":{"exercise_price":10.65,"expiration_date":"2034-10-07","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-25-051349","document":"tm2515648-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000110465925051349/tm2515648-10_4seq1.xml","form_type":"4"}},{"id":1139150,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-21T13:26:25.000Z","date":"2025-05-21","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30541,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Paratek Pharmaceuticals, Inc., a Delaware corporation (\"Parent\"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the \"Effective Time')."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the \"Cash Consideration\") and (ii) one contractual contingent value right (\"CVR\") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, (i) each outstanding and vested restricted stock unit (\"RSU\") was canceled, with the holder thereof entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR and (ii) each outstanding and unvested RSU was canceled, with the holder thereof contingently entitled to receive, with respect to each share of Common Stock underlying such award (A) the Cash Consideration and (B) one CVR, with such consideration vesting and becoming payable, if at all, at the same time as the unvested RSU would have vested and been payable pursuant to its terms."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-051349","document":"tm2515648-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000110465925051349/tm2515648-10_4seq1.xml","form_type":"4"}},{"id":1243503,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-27T01:00:43.000Z","date":"2025-02-21","kind":"grant","planned":false,"acquired":true,"shares":6950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable over a four-year period commencing on February 21, 2025. Twenty-five percent (25%) of the option vests and becomes exercisable on February 21, 2026, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer."}],"balance_after":6950,"derivative":{"exercise_price":5.77,"expiration_date":"2035-02-21","underlying":"Common Stock","underlying_shares":6950},"source":{"system":"sec-edgar","filing":"0001494650-25-000011","document":"wk-form4_1740618037.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000149465025000011/wk-form4_1740618037.xml","form_type":"4"}},{"id":1243502,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-27T01:00:43.000Z","date":"2025-02-21","kind":"grant","planned":false,"acquired":true,"shares":13875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on February 21, 2026, and the balance vests in equal quarterly installments over the remaining three years of the four year period, subject to continued service with the Issuer.  Each RSU represents the right to receive one share of common stock of OptiNose, Inc."}],"balance_after":23875,"source":{"system":"sec-edgar","filing":"0001494650-25-000011","document":"wk-form4_1740618037.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000149465025000011/wk-form4_1740618037.xml","form_type":"4"}},{"id":1280431,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-06T21:15:13.000Z","date":"2023-08-24","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit (\"RSU\") awards with performance based vesting, which were originally granted in March 2023. The RSUs vested 50% upon the first commercial sale of VP-102 on August 24, 2023, and the remaining 50% vested on August 24, 2024, the one year anniversary of the first sale."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of RSUs awarded in the initial Form 4 was unintentionally misreported, as only the number of shares that vested on August 24, 2023 were reported as opposed to the full size of the award. This amendment corrects the number RSUs awarded and the number of securities beneficially owned after the reported transaction."}],"balance_after":125000,"source":{"system":"sec-edgar","filing":"0001415889-25-003233","document":"form4a-02062025_040208.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000141588925003233/form4a-02062025_040208.xml","form_type":"4/A","original_submission_date":"2023-08-28"}},{"id":1390232,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-07T22:40:11.000Z","date":"2024-10-07","kind":"grant","planned":false,"acquired":true,"shares":675000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable over a four-year period commencing on October 7, 2024. Twenty-five percent (25%) of the option vests and becomes exercisable on October 7, 2025, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer."}],"balance_after":675000,"derivative":{"exercise_price":0.71,"expiration_date":"2034-10-07","underlying":"Common Stock","underlying_shares":675000},"source":{"system":"sec-edgar","filing":"0001494650-24-000145","document":"wk-form4_1728340805.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000149465024000145/wk-form4_1728340805.xml","form_type":"4"}},{"id":1390231,"issuer":{"id":79464,"kind":"organization","name":"OptiNose, Inc.","symbol":"OPTN"},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-07T22:40:11.000Z","date":"2024-10-07","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on October 7. 2025, and the balance vests in equal quarterly installments over the remaining three years of the four year period, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of OptiNose, Inc."}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0001494650-24-000145","document":"wk-form4_1728340805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000149465024000145/wk-form4_1728340805.xml","form_type":"4"}},{"id":1421010,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-28T20:15:08.000Z","date":"2024-08-27","kind":"sale","planned":false,"acquired":false,"shares":7899,"price":2.46,"value":19431.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.40 to $2.53 inclusive."}],"balance_after":44697,"source":{"system":"sec-edgar","filing":"0001415889-24-022424","document":"form4-08282024_040804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000141588924022424/form4-08282024_040804.xml","form_type":"4"}},{"id":1421009,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-28T20:15:08.000Z","date":"2024-08-26","kind":"sale","planned":false,"acquired":false,"shares":21820,"price":2.66,"value":58041.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the settlement of the restricted stock units. This sale was mandated by the Issuer's election under its 2018 equity incentive plan to require the satisfaction of minimum statutory tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.53 to $2.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":52596,"source":{"system":"sec-edgar","filing":"0001415889-24-022424","document":"form4-08282024_040804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000141588924022424/form4-08282024_040804.xml","form_type":"4"}},{"id":1569410,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-19T20:31:05.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the total shares subject to the option shall vest on March 15, 2025 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":4.8,"expiration_date":"2034-03-15","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001415889-24-008541","document":"form4-03192024_040349.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000141588924008541/form4-03192024_040349.xml","form_type":"4"}},{"id":1569409,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-19T20:31:05.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs shall vest in equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028 subject to the Reporting Person's continuous service through each applicable date."}],"balance_after":74416,"source":{"system":"sec-edgar","filing":"0001415889-24-008541","document":"form4-03192024_040349.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000141588924008541/form4-03192024_040349.xml","form_type":"4"}},{"id":1739325,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-16T21:34:52.000Z","date":"2023-11-15","kind":"sale","planned":false,"acquired":false,"shares":9632,"price":2.97,"value":28607.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $3.00 inclusive."}],"balance_after":34416,"source":{"system":"sec-edgar","filing":"0001209191-23-055531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000120919123055531/doc4.xml","form_type":"4"}},{"id":1739324,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-16T21:34:52.000Z","date":"2023-11-14","kind":"sale","planned":false,"acquired":false,"shares":18452,"price":2.93,"value":54064.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3)."}],"balance_after":44048,"source":{"system":"sec-edgar","filing":"0001209191-23-055531","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000120919123055531/doc4.xml","form_type":"4"}},{"id":1795437,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-28T20:40:34.000Z","date":"2023-08-24","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents vesting of shares of common stock underlying performance stock units resulting from the achievement of certain non-financial milestones. These shares have not been delivered."}],"balance_after":62500,"source":{"system":"sec-edgar","filing":"0001209191-23-047524","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000120919123047524/doc4.xml","form_type":"4"}},{"id":1974681,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-03-03T21:27:33.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares subject to the option shall vest on March 1, 2024 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":85000,"derivative":{"exercise_price":7.58,"expiration_date":"2033-02-28","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001209191-23-015503","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000120919123015503/doc4.xml","form_type":"4"}},{"id":2372454,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-25T21:33:53.000Z","date":"2022-02-24","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares subject to the option shall vest on February 24, 2023 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":8,"expiration_date":"2032-02-23","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-22-013196","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000120919122013196/doc4.xml","form_type":"4"}},{"id":2629411,"issuer":{"id":6823,"kind":"organization","name":"Verrica Pharmaceuticals Inc."},"owners":[{"id":29785,"kind":"person","name":"Kohler Terry","position":1,"cik":"0001872285","reported_name":"Kohler Terry","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-07-20T22:04:23.000Z","date":"2021-07-16","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares subject to the option shall vest on July 16, 2022 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":125000,"derivative":{"exercise_price":10.28,"expiration_date":"2031-07-15","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-21-047477","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1872285/000120919121047477/doc4.xml","form_type":"4"}}]}